StockData

Palatin Technologies vs Rani Therapeutics

PTN and RANI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PTN and RANI compare

Rani Therapeutics is the larger company, worth 6.9 times as much as Palatin Technologies ($75.3M against $10.9M).

Palatin Technologies scores higher on the StockData Score (6 against 3 for Rani Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPTNRANI
Size and price
Market cap$10.9M$75.3M
Share price$6.13$0.540
Change, 1 year−43.3%−72.0%
Change, 5 years−99.1%−98.2%
Beta (5Y)−0.071.60
Employees2569
StockData Score
Total score6 (better)3
Valuation score11
Growth score11
Performance score00
Health score4 (better)1
Dividend score00
Valuation
P/S–15.4×
P/B1.6× (better)1.9×
FCF yield−125%−27.0% (better)
Fair value–$0.388
Margin of safety–−39.1%
Growth
Revenue growth (TTM)–306%
Revenue growth, 5Y average–28.7%
Profitability
Operating margin–−676%
Net margin–−618%
FCF margin–−417%
Return on equity−878%−179% (better)
Return on invested capital–−145%
Financial health
Debt / equity0.00–
Interest coverage−1288.8×−28.2× (better)
Current ratio4.615.31 (better)
Altman Z-score−75.67−0.67 (better)
Piotroski F-score45 (better)
Dividends and buybacks
Buyback yield−155%–
Shareholder yield−155%0.00% (better)
Ownership
Held by institutions38.5%32.7%
Held by insiders20.6%30.6%
Insider net buying, 12 months−$9.5K$49.7K (better)
Short interest, % of float20.9%8.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.